Posted by Michael Wonder on 02 Jun 2022
TLV reconsiders subsidy of the IL-17 and IL-23 inhibitors
2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors.
Bimzelx, Cosentyx, Kyntheum, Skyrizi, Stelara, Talz and Tremfya are included in the drug benefits. All products except Stelara have a limited subsidy and the subsidy restrictions differ between other products.
Following the decision on subsidy, the costs of alternative treatments have been reduced.
